[HTML][HTML] Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
D Hyun, CM Choi, DH Lee, SW Kim, S Yoon, WS Kim… - PLoS …, 2020 - journals.plos.org
In patients with epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
[HTML][HTML] Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
D Hyun, CM Choi, DH Lee, SW Kim, S Yoon, WS Kim… - PLoS ONE, 2020 - ncbi.nlm.nih.gov
In patients with epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
DG Hyun, CM Choi, DH Lee, SW Kim, S Yoon… - PloS …, 2020 - pubmed.ncbi.nlm.nih.gov
In patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
[引用][C] Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
D Hyun, CM Choi, DH Lee, SW Kim, S Yoon… - PLoS …, 2020 - ui.adsabs.harvard.edu
Outcomes according to initial and subsequent therapies following intracranial progression in
patients with EGFR-mutant lung cancer and brain metastasis - NASA/ADS Now on home …
patients with EGFR-mutant lung cancer and brain metastasis - NASA/ADS Now on home …
[PDF][PDF] Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
H Dg, CM Choi, DH Lee, SW Kim, S Yoon… - PLoS …, 2020 - pdfs.semanticscholar.org
In patients with epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
D Hyun, CM Choi, DH Lee, SW Kim, S Yoon, WS Kim… - PLoS ONE, 2020 - go.gale.com
In patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
D Hyun, CM Choi, DH Lee, SW Kim, S Yoon… - PLoS …, 2020 - search.ebscohost.com
In patients with epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
DG Hyun, CM Choi, DH Lee, SW Kim, S Yoon, WS Kim… - Plos one, 2020 - europepmc.org
In patients with epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …
(NSCLC) with brain metastases, it remains controversial whether the use of EGFR-tyrosine …